Activities of Cristian-Silviu BUŞOI related to 2019/2816(RSP)
Institutional motions (1)
MOTION FOR A RESOLUTION on a strategic approach to pharmaceuticals in the environment
Amendments (16)
Amendment 11 #
Citation 10 a (new)
- having regard to the Council conclusions of 24 June 2019 on the next steps towards making the EU a best practice region in combatting antimicrobial resistance,
Amendment 17 #
Citation 17 a (new)
- having regard to the Commission Communication of the 11 December 2019 entitled ‘European Green Deal’ (COM(2019) 640),
Amendment 27 #
Citation 22 a (new)
- having regard to the OECD study of November 2019 Pharmaceutical Residues in Freshwater - Hazards and Policy Responses,
Amendment 55 #
Recital E
E. whereas pharmaceuticals authorised for human use put on the market before 2006 were not subject to an environmental risk assessment as part of the authorisation process and might therefore still lack such an assessment;
Amendment 68 #
Recital L
Amendment 78 #
Paragraph 3
3. Notes however with concern the veryTakes note of the soft nature of the measurerecommendations included in the communication; considers that legislative measures are needed in addition to non-legislative measures to properly tackle pharmaceutical pollution as these are driven by objectives to pursue, whereas the measures to be taken are of Member State competence; considers that effective measures are needed and should be science-driven and risk-based;
Amendment 90 #
Paragraph 5
5. Considers that a holistic approach is needed to tackle pharmaceutical pollutionmulti stakeholder and coordinated approach is needed to tackle the negative impacts of pharmaceuticals in the environment, taking into account the entire life cycle of drugs; stresses that regulatory actions have to be taken in line with the precautionary principle; highlights that the polluter pays principle should apply, primarily covering the manufacturing process, but also incentivising better prescription practices and consumer behaviourmedicines by designing and implementing a policy mix that combines source- directed, use-oriented and end-of-pipe- measures using a combination of voluntary, economic and regulatory instruments;
Amendment 120 #
Paragraph 10
10. Asks for a special focus to be put on emission hot spots, such as hospitals and pharmaceutical production plants, and waste water treatment plants;
Amendment 128 #
Paragraph 11
11. Calls on the Commission to facilitate the exchange of existing best practices, including those developed by stakeholders, such as iPiE, the Eco- Pharmaco-Stewardship(EPS), the AMR Alliance manufacturing framework and the #MedsDisposal campaign;
Amendment 132 #
Paragraph 11 a (new)
11 a. Encourages that those existing and self-regulated initiatives should be analysed and, where appropriate, considered as models in future EU initiatives on pharmaceuticals in the environment;
Amendment 153 #
Paragraph 15
15. Calls on Member States and the Commission to support theand set financial incentives for research and development of pharmaceuticals intrinsically less harmful for the environment (‘greener pharmaceuticals’), which degrade more readily, into harmless substances, in wastewater treatment plants and the environment, by reducing, as far as possible, the pharmaceutical characteristics that affect environmental risks such as ecotoxicity, persistence, mobility and bioaccumulation;
Amendment 158 #
Paragraph 16
Amendment 180 #
Paragraph 21 a (new)
21 a. Calls on the Commission to include compulsory environmental criteria in the Good Manufacturing Practice (GMP) framework to give EU inspectors the ability to control manufacturing discharges at overseas pharmaceutical factories supplying the EU market;
Amendment 186 #
Paragraph 22
22. Considers that a clear road map for completing environmental risk assessments is needed, where those are not availablealls on the Commission to initiate a systematic catching-up procedure for medicinal products for human use authorised without an environmental risk assessment;
Amendment 218 #
Paragraph 29
29. Considers that pharmaceutical production plants should pre-treat their wastewater applying best available techniques;
Amendment 223 #
Paragraph 30
30. Calls foron Member States to set up and fully enforcement of the existing provisions with regard to take- back schemes for unused medicines;